First attempts in targeting galectins in breast cancer have already been made: Grosset et al. demonstrated that targeting CRD-independent cytosolic Gal-7 in breast cancer cells, and therefore impairing p53-functions, might be a valuable strategy for the treatment of breast cancer [35]. Here, TP53 is linked to breast carcinoma.